Emerging Healthcare Solutions completes acquisition of “Dreams” telemedicine technology

NewsGuard 100/100 Score

Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) announced the Closing of its acquisition of the “Dreams” telemedicine technology today. The Company agreed to pay $800,000 to acquire the rights to this exciting medical communications technology.

The Company had earlier licensed certain rights to this technology but has now completed its due diligence and acquisition so that it will have complete control over the future development and direction of the Dreams system. The Dreams technology was originally developed under an $18 million dollar grant from the Department of Defense.

The Company believes that this technology will play an important role as a platform for introducing further medical communications tools that will allow patients to remotely connect with doctors and hospitals for diagnostic and treatment purposes. This allows for faster diagnosis and treatment while reducing medical costs. The Company expects the use of telemedicine to grow exponentially over the next five years as pressure continues to increase efficiency and reduce health care costs.

Emerging Healthcare Solutions focuses on enabling new potentially profitable medical technology to become a reality in an industry that includes Medtronic, Inc. (NYSE: MDT), Alcon, Inc. (NYSE: ALC), Quest Diagnostics, Inc. (NYSE: DGX) and Heartware International (NASDAQ: HTWR).

Source:

Emerging Healthcare Solutions, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Racial disparities found in delayed COVID-19 testing among healthcare workers